Inventor

DE FOUGEROLLES ANTONIN

BE104 patents

⚠️ This page may combine multiple inventors who share the name “DE FOUGEROLLES ANTONIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

DE FOUGEROLLES ANTONIN

MODERNA THERAPEUTICS INC

Modified polynucleotides encoding hepatitis A virus cellular receptor 2

Modified polynucleotides for the production of oncology-related proteins and peptides

In vivo production of proteins

Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

Modified polynucleotides encoding apoptosis inducing factor 1

Modified polynucleotides for the production of nuclear proteins

Modified polynucleotides for the production of proteins

Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders

Modified polynucleotides encoding aquaporin-5

In vivo production of proteins

Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders

Modified polynucleotides for the production of secreted proteins

Modified polynucleotides encoding citeD4

Modified polynucleotides encoding basic helix-loop-helix family member E41

Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1

Modified polynucleotides for treating galactosylceramidase protein deficiency

Modified polynucleotides for treating protein deficiency

Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

Modified polynucleotides for the production of nuclear proteins

Modified polynucleotides encoding septin-4

Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator

Compositions and methods of altering cholesterol levels

Formulation and delivery of PLGA microspheres

Modified polynucleotides encoding granulysin

MODERNATX INC

Terminally modified RNA

Delivery and formulation of engineered nucleic acids

Delivery and formulation of engineered nucleic acids

Modified Polynucleotides for the production of biologics and proteins associated with human disease

Modified polynucleotides for the production of secreted proteins

In vivo production of proteins

Modified polynucleotides for the production of secreted proteins

In vivo production of proteins

Alternative nucleic acid molecules and uses thereof

Enzymes and polymerases for the synthesis of RNA

Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

Delivery and formulation of engineered nucleic acids

Modified polynucleotides

Modified polynucleotides for the production of secreted proteins

Terminally modified RNA

Modified polynucleotides for the production of biologics and proteins associated with human disease

modeRNA Therapeutics

Split dose administration

Modified polynucleotides for the production of biologics and proteins associated with human disease

Modified polynucleotides for the production of G-CSF

Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides

Method for producing a protein of interest in a primate

ALNYLAM PHARMACEUTICALS INC

RNAi modulation of HIF-1 and therapeutic uses thereof

iRNA agents targeting VEGF

IRNA agents targeting VEGF

SCHRUM JASON P

Engineered nucleic acids encoding a modified erythropoietin and their expression